Entertainment news, movies, and celebrities
Skylark Bio has initiated a clinical trial aimed at treating hearing loss in children with GJB2 mutations, following advancements in gene therapy.
Abortion care is evolving, with patients increasingly turning to digital solutions for reliable information and medical guidance.
MoonLake Immunotherapeutics faces scrutiny for vague disclosures on its autoimmune drug candidate, raising questions about its trial results’ credibility.
Medicare's “Bridge” program aims to lower costs for GLP-1 medications, yet its complexity may hinder patient access to affordable treatments.
The recent Senate hearings on Covid-19's origins spotlight political distractions, while China's suppression of information remains a pivotal issue.
The NIH's proposed changes to funding eligibility may limit opportunities for international researchers on visas in the U.S. biomedical sector.
As Boston's biotech sector grapples with talent migration to California, new discoveries in Alzheimer's research signal both change and opportunity.
As AI tools proliferate in healthcare, the erosion of physician autonomy raises questions about clinical judgment, responsibility, and professional independence.
Felix Wong's biotech startup thrives in California's culture despite his Massachusetts roots and impressive academic pedigree.
A recent Medicare policy change has postponed the price negotiations for a major AbbVie drug, potentially impacting taxpayers significantly.
A recent study reveals tau protein’s unexpected influence on cellular function, suggesting novel strategies for Alzheimer’s treatment.
The FDA has recently approved a new therapeutic drug and a vaccine, shaping the future direction of biotechnology and addressing pressing health needs.
Federal health officials convene with major tech firms to discuss the future of clinical AI, aiming for safe implementation and regulatory clarity.
A clinical trial indicates potential for fecal microbiome transplants to improve peanut allergy tolerance, exciting experts in the field.
A child’s death in a CRISPR gene-editing trial by HuidaGene raises serious concerns about safety and regulatory oversight in China’s biotech sector.
Moderna has launched a clinical trial for its mRNA-based Ebola vaccine, marking a significant step in combating this viral disease.
A recent Medicare pilot proposal risks reducing savings for retail drugs. Meanwhile, merger talks between AstraZeneca and Bristol Myers Squibb have been denied.
A new Medicaid toolkit emphasizes stricter oversight and measurable outcomes for autism therapies, raising concerns around ABA services and telehealth.
Excluding rare disease therapies from Medicare's drug pricing pilots could significantly reduce overall savings, according to recent research.
Despite high diagnosis rates, many U.S. men miss out on MRI screenings for prostate cancer, which could lead to better outcomes.